跳至主要内容
临床试验/NCT04374591
NCT04374591Unknown不适用

The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia: A Preliminary Report of Short Term Follow up

Mansoura University1 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2020年8月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
180
试验地点
1
主要终点
Time to clinical recovery

研究概览

简要总结

To report the possible role of S.B 8.4% in the treatment of COVID-19pneumonia.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age >18 years.
  • Fever ≥ 38º C with upper respiratory tract manifestations, generalized bone ache with or without gastrointestinal symptoms as diarrhea.
  • Chest CT with signs suggestive of COVID-
  • Mild and moderate cases of COVID-19 pneumonia with respiratory and hemodynamic stability. - High C reactive protein (CRP).- With or without history of contact with index case who is isolated in a governmental hospital assigned for treatment of patients proved to have RT-PCR positive test for COVID-19
  • With or without abnormalities in the total or differential white cell count.
  • Welling to sign a fully informed consent.

排除标准

  • Severe and critical illness with respiratory failure and/ or hemodynamic instability.
  • CT with pleural effusion with or without lung cavitation.
  • Other organ failure.

研究组 & 干预措施

Sodium Bicarbonate

Other

Inhalation of Sodium Bicarbonate 8.4% via nebulizer

干预措施: Sodium Bicarbonate (Drug)

Control

Placebo Comparator

placebo

干预措施: Sodium Bicarbonate (Drug)

结局指标

主要结局

Time to clinical recovery

时间窗: 7 days

defined as return of body temperature and relief of cough for more than 72 hours measured in days

次要结局

  • Pulmonary recovery status(7 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验